Healthcare resource use in XALIA: A subgroup analysis of a non-interventional study of rivaroxaban versus standard anticoagulation for deep vein thrombosis-Reference-Cited by-同舟云学术

Healthcare resource use in XALIA: A subgroup analysis of a non-interventional study of rivaroxaban versus standard anticoagulation for deep vein thrombosis

Published:2019-03 Issue: Volume:61 Page:29-33
ISSN:0953-6205
Container-title:European Journal of Internal Medicine
language:en
Short-container-title:European Journal of Internal Medicine

Author:

Mantovani Lorenzo G.,Haas Sylvia,Kreutz Reinhold,Folkerts Kerstin,Gebel Martin,Monje Danja,Schneider Jonas,van Eickels Martin,Sahin Kurtulus,Zell Elizabeth,Ageno Walter,Turpie Alexander G.G.

Funder

Bayer AG

Janssen Research & Development, LLC

Publisher

Elsevier BV

Subject

Internal Medicine

Reference20 articles.

1. Admission rates for emergency department patients with venous thromboembolism and estimation of the proportion of low risk pulmonary embolism patients: A US perspective;Singer;Clin Exp Emerg Med,2016

2. Oral rivaroxaban for symptomatic venous thromboembolism;The EINSTEIN Investigators;N Engl J Med,2010

3. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism;The EINSTEIN–PE Investigators;N Engl J Med,2012

4. Treatment of deep vein thrombosis: what factors determine appropriate treatment?;Douketis;Can Fam Physician,2005

5. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism;The Columbus Investigators;N Engl J Med,1997

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of oral anticoagulation choice on healthcare utilization for the primary treatment of venous thromboembolism;Vascular Medicine;2020-07-27

2. Healthcare resource utilization and costs associated with venous thromboembolism in cancer patients treated with anticoagulants;Journal of Medical Economics;2019-06-12

3. Direct Oral Anticoagulant Drugs: On the Treatment of Cancer-Related Venous Thromboembolism and their Potential Anti-Neoplastic Effect;Cancers;2019-01-05